Literature DB >> 8298812

Attenuation by phentolamine of hypoxia and levcromakalim-induced abbreviation of the cardiac action potential.

D Tweedie1, G Boachie-Anash, C G Henderson, K A Kane.   

Abstract

1. The effects of phentolamine (5-30 microM) and glibenclamide (10 microM) on action potential characteristics were examined in guinea-pig papillary muscle exposed to either hypoxia or levcromakalim (20 microM). 2. The hypoxia-induced abbreviation of action potential duration (APD) and effective refractory period (ERP) were attenuated but not abolished by glibenclamide (10 microM). Hypoxia reduced APD by 24 +/- 2 vs 65 +/- 4% in glibenclamide- and vehicle-treated tissue, respectively. 3. Phentolamine (10-30 microM) was less effective than glibenclamide in attenuating the hypoxic shortening of APD since APD was reduced by 38 +/- 10, 51 +/- 6% vs 65 +/- 4% in 10 and 30 microM phentolamine and vehicle-treated muscle, respectively. 4. Phentolamine, at concentrations of 10 and 30 microM, also reduced the upstroke velocity of the action potential and at 5 microM it increased the APD from 193 +/- 9 to 221 +/- 12 ms. 5. Glibenclamide completely abolished and phentolamine (30 microM) significantly attenuated levcromakalim-induced changes in duration and ERP. Levcromakalim reduced APD by 71 +/- 2 and 55 +/- 2% in control and phentolamine pretreated muscle, respectively. 6. It is concluded that phentolamine may block KATP channels at concentrations that also block sodium channels.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298812      PMCID: PMC2175781          DOI: 10.1111/j.1476-5381.1993.tb13945.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea.

Authors:  P F Kantor; W A Coetzee; E E Carmeliet; S C Dennis; L H Opie
Journal:  Circ Res       Date:  1990-02       Impact factor: 17.367

2.  Influence of ATP-sensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts.

Authors:  C D Wolleben; M C Sanguinetti; P K Siegl
Journal:  J Mol Cell Cardiol       Date:  1989-08       Impact factor: 5.000

3.  The potassium channel opener cromakalim (BRL 34915) activates ATP-dependent K+ channels in isolated cardiac myocytes.

Authors:  D Escande; D Thuringer; S Leguern; I Cavero
Journal:  Biochem Biophys Res Commun       Date:  1988-07-29       Impact factor: 3.575

4.  Characterization of responses to cromakalim and pinacidil in smooth and cardiac muscle by use of selective antagonists.

Authors:  G A McPherson; J A Angus
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

5.  BRL 34915 (cromakalim) activates ATP-sensitive K+ current in cardiac muscle.

Authors:  M C Sanguinetti; A L Scott; G J Zingaro; P K Siegl
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  Block of ATP-regulated potassium channels by phentolamine and other alpha-adrenoceptor antagonists.

Authors:  M J Dunne
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

7.  Cromakalim-induced relaxation of guinea-pig isolated trachealis: antagonism by glibenclamide and by phentolamine.

Authors:  M A Murray; J P Boyle; R C Small
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

8.  Effect of glibenclamide on extracellular potassium accumulation and the electrophysiological changes during myocardial ischaemia in the arterially perfused interventricular septum of rabbit.

Authors:  M N Hicks; S M Cobbe
Journal:  Cardiovasc Res       Date:  1991-05       Impact factor: 10.787

9.  Effects of ATP-sensitive K+ channel blockers on the action potential shortening in hypoxic and ischaemic myocardium.

Authors:  H Nakaya; Y Takeda; N Tohse; M Kanno
Journal:  Br J Pharmacol       Date:  1991-05       Impact factor: 8.739

10.  Phentolamine and yohimbine inhibit ATP-sensitive K+ channels in mouse pancreatic beta-cells.

Authors:  T D Plant; J C Henquin
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.